JP6959924B2 - Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法 - Google Patents

Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法 Download PDF

Info

Publication number
JP6959924B2
JP6959924B2 JP2018534502A JP2018534502A JP6959924B2 JP 6959924 B2 JP6959924 B2 JP 6959924B2 JP 2018534502 A JP2018534502 A JP 2018534502A JP 2018534502 A JP2018534502 A JP 2018534502A JP 6959924 B2 JP6959924 B2 JP 6959924B2
Authority
JP
Japan
Prior art keywords
mmhg
group
substituted
compound
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018534502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528273A (ja
JP2018528273A5 (enExample
Inventor
ケビン ジーン ピータース，
Original Assignee
エアーピオ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアーピオ ファーマシューティカルズ， インコーポレイテッド filed Critical エアーピオ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018528273A publication Critical patent/JP2018528273A/ja
Publication of JP2018528273A5 publication Critical patent/JP2018528273A5/ja
Priority to JP2021165943A priority Critical patent/JP7451472B2/ja
Application granted granted Critical
Publication of JP6959924B2 publication Critical patent/JP6959924B2/ja
Priority to JP2024033979A priority patent/JP2024061772A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018534502A 2015-09-23 2016-09-22 Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法 Active JP6959924B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021165943A JP7451472B2 (ja) 2015-09-23 2021-10-08 Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法
JP2024033979A JP2024061772A (ja) 2015-09-23 2024-03-06 Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222481P 2015-09-23 2015-09-23
US62/222,481 2015-09-23
PCT/US2016/053107 WO2017053566A1 (en) 2015-09-23 2016-09-22 Methods of treating intraocular pressure with activators of tie-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021165943A Division JP7451472B2 (ja) 2015-09-23 2021-10-08 Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法

Publications (3)

Publication Number Publication Date
JP2018528273A JP2018528273A (ja) 2018-09-27
JP2018528273A5 JP2018528273A5 (enExample) 2019-10-31
JP6959924B2 true JP6959924B2 (ja) 2021-11-05

Family

ID=58276474

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018534502A Active JP6959924B2 (ja) 2015-09-23 2016-09-22 Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法
JP2021165943A Active JP7451472B2 (ja) 2015-09-23 2021-10-08 Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法
JP2024033979A Withdrawn JP2024061772A (ja) 2015-09-23 2024-03-06 Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021165943A Active JP7451472B2 (ja) 2015-09-23 2021-10-08 Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法
JP2024033979A Withdrawn JP2024061772A (ja) 2015-09-23 2024-03-06 Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法

Country Status (15)

Country Link
US (3) US10952992B2 (enExample)
EP (3) EP3977994B1 (enExample)
JP (3) JP6959924B2 (enExample)
KR (1) KR20180054677A (enExample)
CN (2) CN113713101B (enExample)
AU (2) AU2016326510C1 (enExample)
BR (1) BR112018005499A2 (enExample)
CA (1) CA2998673C (enExample)
ES (2) ES2894802T3 (enExample)
IL (1) IL258150B (enExample)
MX (2) MX387804B (enExample)
MY (1) MY194736A (enExample)
PH (1) PH12018500658A1 (enExample)
SG (1) SG10201912000WA (enExample)
WO (1) WO2017053566A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MY194736A (en) * 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
CN113286580A (zh) * 2018-07-13 2021-08-20 西北大学 青光眼中的ve-ptp抑制
WO2020214851A1 (en) * 2019-04-18 2020-10-22 Aerpio Pharmaceuticals, Inc. Methods of treating hypertension with activators of tie-2
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
CA3156225A1 (en) 2019-10-29 2021-05-06 EyePoint Pharmaceuticals, Inc. Small molecule activators of tie-2
AU2021205472A1 (en) * 2020-01-08 2022-06-30 EyePoint Pharmaceuticals, Inc. Combinations of Tie-2 activators and prostaglandins and uses thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US645503A (en) 1899-05-11 1900-03-13 Timothy Francis Crowley Cutter-gage for ice-cream, & c.
US953924A (en) 1909-06-28 1910-04-05 Dow Wire & Iron Works Sliding door.
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
AU5154098A (en) 1996-10-31 1998-05-22 Duke University Soluble tie2 receptor
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
CA2368670C (en) 1999-03-26 2012-06-05 Chitra Suri Modulation of vascular permeability by means of tie2 receptor activators
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
AU2003229627A1 (en) 2002-04-08 2003-10-20 Max-Planck-Gesellschaft Zur Ve-ptp as regulator of ve-cadherin mediated processes or disorders
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
HUE029852T2 (en) 2004-03-15 2017-04-28 Janssen Pharmaceutica Nv Opioid receptor modulators
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1819355A4 (en) 2004-09-28 2009-08-12 Genexel Sein Inc METHOD OF USE OF A CHIMERIC COILED COIL MOLECULE
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2518083A3 (en) 2005-12-15 2012-12-05 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer
EP2596807B1 (en) 2006-03-08 2015-12-16 Archemix LLC Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
DE102006016426A1 (de) * 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8957022B2 (en) 2006-10-27 2015-02-17 Sunnybrook Health Sciences Centre Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
CA2838846C (en) 2009-01-12 2018-06-19 Aerpio Therapeutics Inc. Compositions and methods for treating brain edema
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
WO2010097800A1 (en) * 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
CN102340993A (zh) 2009-03-03 2012-02-01 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
AU2010221369B2 (en) 2009-03-03 2014-03-13 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US20140010805A1 (en) 2010-07-12 2014-01-09 Karen Curd Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
NZ610230A (en) 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CN103249422A (zh) 2010-12-02 2013-08-14 丸善制药株式会社 Tie2活化剂、血管内皮生长因子抑制剂、血管生成抑制剂、血管成熟剂、血管正常化剂及血管稳定剂、以及药物组合物
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
AU2012323849B2 (en) 2011-10-13 2017-04-20 EyePoint, Inc. Treatment of ocular disease
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
AU2013245630A1 (en) 2012-04-13 2014-10-30 The Johns Hopkins University Treatment of ischemic retinopathies
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
WO2014022455A1 (en) 2012-07-31 2014-02-06 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
US10519226B2 (en) 2012-10-11 2019-12-31 Ascendis Pharma Opthalmology Division A/S VEGF neutralizing prodrugs for the treatment of ocular conditions
KR102467714B1 (ko) 2012-11-08 2022-11-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
WO2014079709A1 (en) 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
ES2743509T3 (es) 2013-04-11 2020-02-19 Sunnybrook Res Inst Métodos, usos y composiciones de agonistas de Tie2
EP3010526A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
US20160137717A1 (en) 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
BR112016000282A2 (pt) 2013-07-11 2017-12-12 Novartis Ag uso de antagonista de vegf em tratamento de retinopatia da prematuridade
WO2015004616A1 (en) 2013-07-11 2015-01-15 Novartis Ag Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
TR201905773T4 (tr) 2013-10-01 2019-05-21 Sphingotec Gmbh Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul.
AU2014342162B2 (en) 2013-11-01 2020-01-02 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US10071850B2 (en) 2014-04-04 2018-09-11 Daizo Corporation Discharge container
WO2015152416A1 (ja) 2014-04-04 2015-10-08 国立大学法人東北大学 眼圧降下剤
US9719135B2 (en) 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
US20160082129A1 (en) 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
MY194736A (en) * 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
WO2020223209A1 (en) * 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal

Also Published As

Publication number Publication date
ES2894802T3 (es) 2022-02-15
AU2022202618B2 (en) 2023-12-14
CN113713101B (zh) 2023-07-28
IL258150B (en) 2021-06-30
SG10201912000WA (en) 2020-02-27
US10952992B2 (en) 2021-03-23
JP2022000482A (ja) 2022-01-04
MX2018003542A (es) 2018-11-09
JP2024061772A (ja) 2024-05-08
US20230398100A1 (en) 2023-12-14
MX387804B (es) 2025-03-19
US20170079959A1 (en) 2017-03-23
MX2021010915A (es) 2021-10-01
CN108290057A (zh) 2018-07-17
EP3352856A1 (en) 2018-08-01
JP2018528273A (ja) 2018-09-27
AU2022202618A1 (en) 2022-05-12
CA2998673C (en) 2023-12-12
MY194736A (en) 2022-12-15
EP3977994B1 (en) 2024-04-24
US11666558B2 (en) 2023-06-06
AU2016326510C1 (en) 2024-06-27
NZ740730A (en) 2024-07-26
IL258150A (en) 2018-05-31
EP3352856B1 (en) 2021-08-18
JP7451472B2 (ja) 2024-03-18
EP3977994A1 (en) 2022-04-06
EP3352856A4 (en) 2019-05-01
US12171751B2 (en) 2024-12-24
BR112018005499A2 (pt) 2018-10-09
NZ780430A (en) 2024-09-27
CA2998673A1 (en) 2017-03-30
AU2016326510B2 (en) 2022-03-10
EP4414032A3 (en) 2024-11-06
KR20180054677A (ko) 2018-05-24
WO2017053566A1 (en) 2017-03-30
ES2981607T3 (es) 2024-10-09
PH12018500658A1 (en) 2018-10-01
CN113713101A (zh) 2021-11-30
AU2016326510A1 (en) 2018-04-12
US20210386713A1 (en) 2021-12-16
EP4414032A2 (en) 2024-08-14
EP3977994C0 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
JP7451472B2 (ja) Ｔｉｅ－２の活性化物質を用いる眼内圧を処置する方法
US20240238279A1 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
CA2314571C (en) Methods and compositions for treating diseases and conditions of the eye
AU2021205472A1 (en) Combinations of Tie-2 activators and prostaglandins and uses thereof
HK40072252A (en) Activators of tie-2 for use in treating intraocular pressure
HK40072252B (en) Activators of tie-2 for use in treating intraocular pressure
JP2022530657A (ja) シュレム管を標的とするＴｉｅ－２活性化物質
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
HK40100601A (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
HK40000009A (zh) 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211008

R150 Certificate of patent or registration of utility model

Ref document number: 6959924

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350